Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8: later-stage trial registry
1 of 2 indexed Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8: 2 US clinical trials tracked, 1 recruiting.
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is NRG Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition stage-i-uterine-corpus-carcinoma-or-carcinosarcoma-ajcc-v8
OPEN 1 | RECR 50% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NRG Oncology
NCT05646316
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
National Cancer Institute (NCI)
NCT04214067
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NRG Oncology sponsors the most Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See NRG Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 condition card totals 2 registered trials; most-linked intervention Biospecimen Collection; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.